ZHEJIANG SHOUXIANGU PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28 CNY | -0.88% |
|
+2.41% | -13.15% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -13.15% | 769M | - | ||
| +42.38% | 6.26B | B- | ||
| -15.86% | 4.49B | C+ | ||
| +6.36% | 3.29B | C | ||
| -11.28% | 3.12B | B- | ||
| -3.23% | 2.5B | - | D+ | |
| +45.24% | 1.94B | - | ||
| -7.89% | 1.68B | - | - | |
| -0.98% | 1.63B | - | - | |
| -11.32% | 1.56B | C- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 603896 Stock
- Ratings Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
